Vertex Pharmaceuticals Inc

XNASHealth care

Last traded price · USD

$538.00

+1.36%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $530.76
Volume: 476
Day's high: —
Day's low: —

In brief

Vertex Pharmaceuticals Inc is a health care company listed on Nasdaq, valued at about $136.36B.
Its shares closed at $530.76 on 3 Nov 2026, up 24.6% over the past year.
From India you can buy VRTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vertex Pharmaceuticals Inc (VRTX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole VRTX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade VRTX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +5.4% (SPY −2.6%, XLV +9.9%). 3 months: +10.9% (SPY −2.2%, XLV +13.5%). 1 year: +24.6% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VRTX, SPY and XLV · as of 3 Nov 2026
Volume 1.8× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 2.4M shares was 1.8× the average of the 30 sessions before it (1.3M), as the price fell 4.0%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
P/E 31.5% below its peers' median
Trailing P/E of 31.3 against a median of 45.7 across 3 peers named in its company record (range 39.5 to 80.8).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $530.76 was 1.5% above its 50-day average ($522.98) and 10.5% above its 200-day average ($480.23). It has closed above the 200-day for 101 sessions, since 11 Jun 2026. The 50-day average crossed above the 200-day on 29 Jun 2026, 89 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
77% of the way up its 52-week range
Closed at $530.76 on 3 Nov 2026: 6.7% below the 52-week high of $568.67 (2 Nov 2026) and 30.5% above the low of $406.67 (7 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+5.4%

6 months+25.1%

1 year+24.6%

5 years+180.7%

Newswire

About

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Website

Notable moves

August 5, 2025
−20.60%
December 19, 2024
−11.37%
December 13, 2023
+13.23%

Newswire

About

Website

Notable moves

August 5, 2025
−20.60%
December 19, 2024
−11.37%
December 13, 2023
+13.23%

Vertex Pharmaceuticals Inc

XNASHealth care

Last traded price · USD

$538.00

+1.36%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 4 Nov 2026, 15:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $530.76
Volume: 476
Day's high: —
Day's low: —

In brief

Vertex Pharmaceuticals Inc is a health care company listed on Nasdaq, valued at about $136.36B.
Its shares closed at $530.76 on 3 Nov 2026, up 24.6% over the past year.
From India you can buy VRTX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vertex Pharmaceuticals Inc (VRTX) shares from India?

Do I need the price of a whole VRTX share to invest?

How much can I invest in US stocks in a year?

Can I trade VRTX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +5.4% (SPY −2.6%, XLV +9.9%). 3 months: +10.9% (SPY −2.2%, XLV +13.5%). 1 year: +24.6% (SPY +10.4%, XLV +27.4%). Price change to the 3 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: VRTX, SPY and XLV · as of 3 Nov 2026
Volume 1.8× its 30-session average on 3 Nov 2026
3 Nov 2026 volume of 2.4M shares was 1.8× the average of the 30 sessions before it (1.3M), as the price fell 4.0%. SPY traded 0.8× its own average that session.
Daily volume against a 30-session baseline · as of 3 Nov 2026
P/E 31.5% below its peers' median
Trailing P/E of 31.3 against a median of 45.7 across 3 peers named in its company record (range 39.5 to 80.8).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 4 Nov 2026
Above its 50- and 200-day averages
The 3 Nov 2026 close of $530.76 was 1.5% above its 50-day average ($522.98) and 10.5% above its 200-day average ($480.23). It has closed above the 200-day for 101 sessions, since 11 Jun 2026. The 50-day average crossed above the 200-day on 29 Jun 2026, 89 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 3 Nov 2026
77% of the way up its 52-week range
Closed at $530.76 on 3 Nov 2026: 6.7% below the 52-week high of $568.67 (2 Nov 2026) and 30.5% above the low of $406.67 (7 Nov 2025).
Daily price bars, split-adjusted · as of 3 Nov 2026

Returns

Price return, split-adjusted

At the 3 Nov 2026 close

1 month+5.4%

6 months+25.1%

1 year+24.6%

5 years+180.7%

Newswire

About

Website

Notable moves

August 5, 2025
−20.60%
December 19, 2024
−11.37%
December 13, 2023
+13.23%

Newswire

About

Website

Notable moves

August 5, 2025
−20.60%
December 19, 2024
−11.37%
December 13, 2023
+13.23%

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Volume 1.8× its 30-session average on 3 Nov 2026

P/E 31.5% below its peers' median

Above its 50- and 200-day averages

77% of the way up its 52-week range

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc in brief

Ahead of SPY, behind its sector fund XLV over 1 year

Volume 1.8× its 30-session average on 3 Nov 2026

P/E 31.5% below its peers' median

Above its 50- and 200-day averages

77% of the way up its 52-week range